Journal
CANCER LETTERS
Volume 280, Issue 1, Pages 1-14Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.10.045
Keywords
Met; Receptor tyrosine kinase; Targeted therapy; Hepatocyte growth factor
Categories
Funding
- NCI, Department of Health and Human Services [CA85915]
- Center for Targeted Therapy of the University of Texas M.D. Anderson Cancer Center
Ask authors/readers for more resources
Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available